Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant811 active trials6 approved drugs154 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,934 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789379 | Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | not yet recruiting | Phase 2 | 94 | Wei JiangOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07791264 |
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma |
| not yet recruiting |
| Phase 1 |
| 24 |
| City of Hope Medical CenterOTHER |
| 1 |
| Aug 27, 2026 |
| clinicaltrials |
| NCT03048084 | Seizure Treatment in Glioma(STING) | recruiting | Phase 4 | 120 | Leiden University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05236036 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | active not recruiting | Phase 1 | 86 | Northwestern UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Aug 26, 2026 | clinicaltrials |
| NCT07788430 | Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study(EXPOGLIO) | not yet recruiting | N/A | 120 | Institut Claudius RegaudOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788677 | Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)(TARLAGLIA) | not yet recruiting | Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05504291 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | recruiting | Phase 2 | 26 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT07076472 | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma | recruiting | Early Phase 1 | 8 | Mayo ClinicOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07579208 | A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04214392 | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | active not recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05463848 | Surgical Pembro +/- Olaparib w TMZ for rGBM | active not recruiting | Phase 2 | 52 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06954636 | Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study(OLFGBM) | recruiting | — | 128 | Sied KebirOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07750457 | Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma(GliProPh) | recruiting | N/A | 80 | University Hospital, EssenOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07778979 | Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas | not yet recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01772771 | Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program | recruiting | — | 12,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07209241 | Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07485049 | BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | recruiting | Early Phase 1 | 78 | Nader SanaiOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02658279 | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | active not recruiting | N/A | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04737577 | Glioma Supra Marginal Incision Trial(G-SUMIT) | completed | N/A | 44 | Sunnybrook Health Sciences CentreOTHER | 2 | Aug 20, 2026 | clinicaltrials |
| NCT05180825 | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy(PLGG - MEKTRIC) | recruiting | Phase 2 | 134 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05632562 | Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma | recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05676489 | MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors | not yet recruiting | Early Phase 1 | 28 | University of Alabama at BirminghamOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775534 | Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients | not yet recruiting | N/A | 30 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | recruiting | Phase 2 | 460 | David Reardon, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06108206 | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | active not recruiting | — | 20 | Columbia UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04047264 | Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04485559 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | recruiting | Phase 1 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04903795 | BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma(BRiTE) | recruiting | Phase 1 | 18 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06319027 | Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial(GABLE) | recruiting | Phase 2 | 100 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07769918 | Hypoxia-targeted Radiotherapy Boost for GBM | not yet recruiting | N/A | 25 | NYU Langone HealthOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04755205 | A Natural History Study of Children and Adults With Olfactory Neuroblastoma | recruiting | — | 525 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05030298 | Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial | recruiting | Phase 1 | 28 | Mayo ClinicOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05095376 | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | active not recruiting | Phase 3 | 265 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05212272 | MRI in High-Grade Glioma Patients Undergoing Chemoradiation | recruiting | N/A | 16 | Wake Forest University Health SciencesOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05607407 | Methimazole in Patients With Progressive Glioblastoma | suspended | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05859334 | Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | active not recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06632236 | 5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD) | active not recruiting | Phase 1 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2026source: clinicaltrials